Core Viewpoint - 百心安-B's stock price increased by nearly 12% following the announcement of the registration of its Iberis RDN system in New Zealand, highlighting positive market sentiment towards the company's advancements in medical technology [1] Company Developments - 百心安-B's subsidiary, Shanghai Antong Medical Technology Co., Ltd., has successfully registered the Iberis RDN system with New Zealand's Medsafe [1] - The Iberis RDN system is the only renal denervation (RDN) product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods, enhancing safety, efficacy, and cost-effectiveness of RDN procedures [1] - The ultimate goal of the company is to provide outpatient RDN surgeries for patients worldwide [1] Market Performance - As of the report, 百心安-B's stock was trading at 6.85 HKD with a trading volume of 430.19 million HKD, reflecting strong investor interest [1]
港股异动 | 百心安-B(02185)午后涨近12% IBERIS® RDN系统在新西兰注册